



Centrum pro výzkum  
toxických látek  
v prostředí

# BIOMARKERS AND TOXICITY MECHANISMS 11 – BIOMARKERS of EXPOSURE and SUSCEPTIBILITY

Luděk Bláha, PŘF MU, RECETOX  
[www.recetox.cz](http://www.recetox.cz)

Tento projekt je spolufinancován Evropským sociálním fondem a státním rozpočtem České republiky.



INVESTICE DO ROZVOJE VZDĚLÁVÁNÍ

# Biomarkers of Exposure

## Biomarkers of internal and effective dose

*depends on toxicokinetics*

### Biomarkers of internal dose (short / long term)

– examples: Cd in urine, DDE in fat tissues

- should be easy to sample (urine, breath)
- instrumental analytical methods (analyses of toxicant)

### Biomarkers of effective dose

- the chemical interacted with the biological target

→ **analyses of ADDUCTS**

Two types of adducts: **selective and non-selective**



# SELECTIVE ADDUCTS OF TOXICANTS with BIOMOLECULES

## SELECTIVE = CHEMICAL-SPECIFIC



Adducts with DNA

styrene-oxide-O6-guanine  
N7-guanyl-aflatoxin B1

Hemoglobin-pesticides adduct



## Methods of analyses:

- analytical chemistry
- extraction from biological sample
- chemical determination by HPLC or GC



**Table 1** Reported human haemoglobin adduct levels for various xenobiotics

Chemical (type of exposure)	Adduct/analyte	Method	Adduct level (nmol g <sup>-1</sup> haemoglobin)
<i>N,N</i> -Dimethylformamide (occupational)	3-Methyl-5-isopropylhydantoin	Hydrolysis; GC-MS	75–1000 (exposed) 4–12 (control)
Epichlorohydrin (occupational)	<i>N</i> -(2, 3-Dihydroxypropyl)valine	Modified Edman; GC-MS	0.020 (exposed smokers) 0.007 (exposed non-smokers) 0.013 (control smokers) 0.007 (control non-smokers)
Acetaminophen (drug overdose)	3-(Cystein- <i>S</i> -yl)acetaminophen	Immunoassay	100–4100
PAHs (occupational)	BPDF-Hb	Spectrofluorimetry	0.005–0.139
Ethylene oxide (occupational)	<i>N</i> -Hydroxyethylvaline	Modified Edman; GC-MS	5–20 (exposed) 0.1–0.5 (control smokers) 0.01–0.1 (control non-smokers)
Ethene (occupational)	<i>N</i> -Hydroxyethylvaline	Modified Edman; GC-MS	0.02
Propylene oxide (occupational)	<i>N</i> -Hydroxypropylvaline	Modified Edman; GC-MS	0.05–3.5 (exposed) < 0.02 (unexposed)
Acrylonitrile (smoking)	<i>N</i> -Cyanoethylvaline	Modified Edman; GC-MS	0.09
NNK (smoking)	4-Hydroxy-1-(3-pyridyl) butan-1-one	Hydrolysis; GC-MS	0.0015 (smokers) 0.0005 (non-smokers)
4-ABP (smoking)	4-ABP-cysteine	Hydrolysis; GC-MS	0.00025–0.0025 (smokers) 0.00005–0.0005 (non-smokers)
Acrylamide (occupational, smoking)	<i>N</i> -(2-Carbamoyl)ethylvaline	Modified Edman; GC-MS	9.5 (production workers) 0.054 (laboratory workers) 0.116 (smokers) 0.031 (non-smokers)
Butadiene (occupational)	<i>N</i> -(2,3,4-Trihydroxybutyl)valine	Modified Edman; GC-MS	0.010–0.014 (exposed) 0.002–0.003 (control)
Styrene (occupational)	2-Phenylethanol	Cleavage with Raney nickel, GC-MS	3.7–8.0 (exposed) 2.0–8.6 (control)



**PAH-DNA adducts**  
 PAH (polycyclic aromatic hydrocarbons)  
 \* often high variability  
 \* may have difficult interpretation

← **Occup. exposure  
 (Low / Intermed. / High)**

← **Occupational  
 Non-exposed (NS)  
 vs.  
 Exposed (S)**

## Non-selective adducts

- binding with macromolecules (DNA, proteins) **with no further information on the structure of actual adduct** (i.e. causative agent not clear)


## Typical nonselective biomarker of exposure methods (for DNA damage)

- $^{32}\text{P}$ -postlabelling assay
- oxidized DNA: 8-hydroxy-2'-deoxyguanosine




# <sup>32</sup>P-postlabelling assay principle

- Digestion of NA
- Enzymatic labelling with <sup>32</sup>P (kinase)
- TLC or HPLC analyses of products



## TLC result (thin layer chromatography)


A - 2-5 = various adducts  
B - controls



## 8-hydroxy-2'-deoxyguanosine analysis

Oxidative damage to DNA


- many causes → 8-OH-dG is the most common marker of DNA oxidation



### Analysis: analytical chemistry methods

- HPLC

- immunochemistry (ELISA)




**Figure 1.** Adjusted urinary 8-OHdG level (ng/mg creatinine) by urinary arsenic and urinary chromium concentrations. Values shown are mean  $\pm$  SE. Cut points were determined according to medians (arsenic, 7.7  $\mu$ g/g creatinine; chromium, 2.0  $\mu$ g/g creatinine) of urinary creatinine-adjusted levels among all subjects.



# Biomarkers of susceptibility





**Figure 2** Representation of the relationships between ambient exposure and critical target dose and the progressive decrease in effective exposure due to various biological barriers. Source: *Low-Dose Extrapolation of Cancer Risks: Issues and Perspectives*, p. 188. Used with permission. © 1995 International Life Sciences Institute, Washington, DC, U.S.A.

## Toxicokinetics


determines susceptibility of an individual at various levels

## → Biomarkers of susceptibility

Will the individual be sensitive?  
Will patient respond to a drug?

**Esp. METABOLISM is important and used as BM of susceptibility (mostly known for prototypical enzymes, like CYPs, for prototypical chemicals such as DRUGS...)**

# Importance of susceptibility biomarkers



**Figure 1** The biomarker paradigm linking exposure with disease and showing expansion of the classical epidemiological 'black box' to reveal discrete mechanistic stages. Reprinted with permission from *Environ. Sci. Technol.* (1997) **31**, pp. 1837-1848. Copyright 1997 American Chemical Society.

# Biomarkers of susceptibility

Susceptibility depends on **genotype and metabolism**

- genetic polymorphism in detoxification enzymes
- variability in specific isoenzymes

→ susceptibility to „activate“ toxicants:


**example: N-acetylation of arylamines – NAT2**

→ susceptibility to genotoxins

→ family cancers

→ susceptibility to drugs (including anticancer drugs)

Example: **genetic polymorphism**  
SNPs - single nucleotide polymorphism



## SNPs


- affects protein functions
- in specific cases (see example) some SNPs identified

## → PERSONALIZED MEDICINE

### To identify SNP as a biomarker

Many **genotypes** (from many individuals) must be sequenced and compared with **phenotype** (e.g. responsiveness to certain drug)

# Cyclophosphamide (anticancer drug) and its toxicity



**Genetic polymorphism**

# Example: genetic polymorphism


## CYP450 Enzymes and Polymorphisms



Diagnostics

Enzyme	Fraction of drug metabolism	Major polymorphisms
CYP3A4	40-45%	Rare
CYP2D6	20-30%	*2xn, *4, *10, *17, *41
CYP2C9	10%	*2, *3
CYP2C19	5%	*2, *3
CYP1A2	5%	*1K
CYP2B6	2-4%	-
CYP2E1	2-4%	-
CYP2A6	2%	*4, *9
CYP2C8	1%	*3
CYP3A5	<1%	*3

Alleles known to be involved in polymorphism



The CYP 2D6 gene is extremely polymorphic with more than 70 allelic variants described so far <sup>1</sup>

Ingelman-Sundberg, TRENDS in Pharmacological Sciences, Vol. 25 No.4 April 2004

<sup>1</sup> Dahl, Clin. Pharmacokinetics 2002; 41 (7): 453-470

AMPLI@HIP




Centrum pro výzkum  
toxických látek  
v prostředí


# Personalized medicine

## Personalized medicine: tailored treatments

Medicine of the present: one treatment fits all



Medicine of the future: more personalized diagnostics




Different people respond differently to the same therapy: while one treatment brings about the desired success in one group of patients with e.g. colon cancer, it does not change the condition of other groups at all, or even leads to adverse effects (left). The reason: the genetic makeup and metabolic profile of each individual patient influences the effect of a drug. Personalized medicine takes these individual patterns of cellular and metabolic products into account in the diagnostic phase: **biomarker diagnostics** separates patients into groups with similar characteristics, and provides information on the best individual treatment. This should enable all patients to benefit from their own, "personal" therapy.


## SNP diagnostics:

- 1) DNA isolation
- 2) Multiplication of specific gene eg. CYP
- 3) SNP identification
  - ... Molecular biology methods such as
  - \* NA sequencing
  - \* Probe pairing ... number of variants

Invader assay in which probe complements the SNP resulting in fluorescence



Invader assay in which probe mismatches at the SNP location preventing cleavage from occurring



Reference: Based on Olivier M. 2005. The Invader assay for SNP genotyping.